PLB-002
/ Primelink Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 04, 2026
A Study of PLB-002 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Primelink BioTherapeitics(ShenZhen) Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Platinum resistant • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6
December 27, 2025
A Study of PLB-002 in Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Primelink BioTherapeitics(ShenZhen) Limited
New P1 trial • Solid Tumor
March 26, 2025
PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer
(AACR 2025)
- "Here, we describe the development and preclinical characterization of a novel ADC called PLB-002, which consists of a highly selective CLDN6 targeting antibody, PLB-002-ab7, conjugated to a FDA-approved microtubule inhibitor, eribulin, via a Primelink Biotherapeutics proprietary enzyme-cleavable linker with an optimized average drug-to-antibody ratio (DAR) of 4.0. These results show that PLB-002 has remarkable antitumor activity and support the clinical development as a therapeutic ADC for the treatment of ovarian cancer and other CLDN6 expressing solid cancer.*, Equal contributions."
Genito-urinary Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN3 • CLDN4 • CLDN6
1 to 3
Of
3
Go to page
1